Cohen, J.; Ward, M. M.; Kornhauser, N.; Chuang, E.; Cigler, T.; Moore, A.; Donovan, D.; Lam, C.; Cobham, M. V.; Schneider, S.; Hurtado Rua, Sandra M.; Benkert, S.; Greenwood, C. Mathijsen; Zelkowitz, R.; Warren, J. D.; Lane, M. E.; Mittal, V.; Rafii, S.; and
Background: Bone marrow-derived endothelial progenitor cells (EPCs) are critical for metastatic progression. This study explores the effect of tetrathiomolybdate (TM), an anti-angiogenic copper chelator, on EPCs in patients at high risk for breast cancer recurrence.
Patients and methods: This phase 2 study enrolled breast cancer patients with stage 3 and stage 4 without evidence of disease (NED), and stage 2 if triple-negative. TM 100 mg orally was administered to maintain ceruloplasmin <17 mg/dl for 2 years or until relapse. The primary end point was change in EPCs.
Results: Forty patients (28 stage 2/3, 12 stage 4 NED) were enrolled. Seventy-five percent patients achieved the copper depletion target by 1 month. Ninety-one percent of triple-negative patients copper-depleted compared with 41% luminal subtypes. In copper-depleted patients only, there was a significant reduction in EPCs/ml by 27 (P = 0.04). Six patients relapsed while on study, of which only one patient had EPCs maintained below baseline. The 10-month relapse-free survival was 85.0% (95% CI 74.6%-96.8%). Only grade 3/4 toxicity was hematologic: neutropenia (3.1% of cycles), febrile neutropenia (0.2%), and anemia (0.2%).
Conclusions: TM is safe and appears to maintain EPCs below baseline in copper-depleted patients. TM may promote tumor dormancy and ultimately prevent relapse.
introduction Despite improvements in adjuvant therapy of breast cancer over the past two decades, there is significant risk of relapse in a high risk subset of patients. Although the definition of high risk has been evolving, it still includes patients with stage 3 breast cancer and those with stage 4 with no evidence of disease (NED). The risk of relapse in stage 3 patients is 50% 75% over 5 years, and patients with stage 4 breast cancer will inevitably recur even when temporarily rendered disease free by surgery, radiation, or chemotherapy [1] . Reflecting the increasing importance of biology over stage, now included in the definition is the triple negative subset [lack of expression of estrogen receptor (ER)/progesterone receptor (PR), nor overexpression of human epidermal growth factor 2 (HER2)]. These patients have a poor prognosis in earlier stages and represent a disproportionately increased percentage with metastatic disease [2 4 ].
The tumor microenvironment and its components, including stromal fibroblasts and endothelial and inflammatory cells, play a major role in the establishment, progression, and metastatic dissemination of cancer [5 11 ]. Using preclinical models of breast cancer that metastasize to the lungs, the premetastatic niche is comprised of recruited bone marrow derived cells, including endothelial progenitor cells (EPCs; CD45 dim , CD133 + , VEGFR2 + ), that modulate the angiogenic switch for the progression of avascularized micrometastases to vascularized macrometastases. VEGFR1 + hematopoietic progenitor cells (HPCs) and CD11b + myeloid progenitor cells establish the premetastatic niche and recruit EPCs, among other cells, to activate this angiogenic switch [12, 13] . EPC deficiency results in impaired macrometastatic formation as a receptor CXCR4, involved in angiogenesis and metastatic progression, may have a role in EPC recruitment [36, 37] . In breast cancer patients, expression of SDF1 has been inversely correlated with survival [38] . In our study, SDF1 decreased with copper depletion but increased before relapse. Likewise, MMPs increased in patients before relapse. MMPs regulate tumor growth and invasion [36] and provide a permissive bone marrow niche to facilitate mobilization of progenitor cells [39] . Our observations suggest that SDF1 and MMPs may have important roles in metastatic progression.
Though a randomized clinical trial is necessary to assess survival, efficacy measures were promising. Of 11 triple negative patients on study, only 2 relapsed. One patient did not adequately copper deplete despite incremental dose increases. The other patient progressed within 2 months of TM therapy, suggesting that active neoangiogenesis was occurring at the time of enrollment, which could not be halted due to delayed effects of copper depletion. We are cautiously optimistic about the low incidence of relapse and have extended the study to 6 years in selected patients. Two stage 4 NED triple negative patients remain disease free at 65 and 49 months on TM therapy, which is encouraging given the dismal median survival of 9 months in metastatic triple negative patients [2] .
In summary, we have conducted the first phase II study employing copper chelation in high risk breast cancer patients with minimal residual disease. As the evidence accumulates in favor of copper depletion to prevent relapse, a large, randomized, multicenter trial enriched with triple negative and stage 4 NED patients may be of utility.
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